Bone Biologics Corporation
BBLGNASDAQHealthcareBiotechnology
Previous close
$0.6262
+$0.0212 · +3.50%
Pre-market
$0.626
−$0.0002 · -0.03%
Aug 24, 4:00 AM ET
BBLG company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
50
Fair Value
Momentum
35
Weakening
Sentiment
56
Mixed
Risk resilience
30
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jeffrey Frelick
- Listed since
- Oct 13, 2021
- Employees
- 2
Market position
Day range
Current $0.6262
52-week range
Current $0.6262
- Open
- $0.6156
- Previous close
- $0.605
- Volume
- 83.38K
- 1.72× average
- Average volume
- 48.41K
- Average daily volume
- Market cap
- 1.13M USD
- Beta
- 0.53
- Market reference 1
- 50-day average
- $1.1115
- -43.66% below average
- 200-day average
- $1.3602
- -53.96% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -3.63M USD
- P/E (TTM)
- -0.34×
- P/B (TTM)
- 0.29×
- P/S (TTM)
- 0×
- EV / EBITDA
- 1.17×
- Earnings yield
- -182.50%
- Free cash flow yield
- -157.97%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -57.81%
- Return on assets
- -53.64%
- Return on invested capital
- -60.16%
Financial health
- Debt / equity
- 0×
- Current ratio
- 13.85×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.06M USD | 2.13M USD | 6.91M USD | 1.58M USD | 82.04K USD |
| Selling, general, and administrative | 2.17M USD | 2.09M USD | 2.52M USD | 2.09M USD | 1.02M USD |
| Operating expenses | 3.23M USD | 4.22M USD | 9.43M USD | 3.67M USD | 1.1M USD |
| Interest income | 121.98K USD | 55.66K USD | 1.87K USD | — | 805.11 USD |
| Interest expense | — | — | — | 731.71K USD | 805.11K USD |
| Depreciation and amortization | — | 4.22M USD | 9.43M USD | — | — |
| Operating income | −3.23M USD | −4.22M USD | −9.43M USD | −3.67M USD | −1.1M USD |
| Net income | −3.11M USD | −4.11M USD | −8.95M USD | −1.48M USD | −1.61M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 4 misses, 1 met estimate
- Average EPS surprise
- +10.41%
- 11 comparable reports
- Latest EPS result
- -0.43
- Estimate -0.39 · Miss by 10.26%
EPS: actual versus estimate
Recent quarterly results
BBLG peers
Continue in GoAI
Research BBLGresearch.disclaimer